ALNY (Alnylam Pharmaceuticals) — Research Report as of 2026-08-03

Summary

ALNY is a leading RNAi therapeutics company that just reported Q2 2026 earnings on July 30, 2026 [4]. The stock has experienced extreme volatility — plummeting as much as 29% on the earnings day [2] — driven by a guidance cut despite a quarter that showed sequential demand acceleration. The stock currently trades around $271.77 [13], well below analyst consensus targets of ~$434–$439 [12][13], which may explain why quantitative screens are flagging it tonight as a top scorer: the gap between price and target has widened dramatically following the sell-off.

---

Recent Catalysts (Last ~1–3 Months)